Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
AxoSim, Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct art units, indicating a focused but multi-disciplinary approach to their biological innovations. The workload involves 2 distinct examiners, ensuring that no single official handles the entirety of the company's active matters. This diversification can be beneficial for risk management, as it prevents the company's entire pending docket from being subject to the specific tendencies of a single individual.
The busiest examiner for this portfolio is MOLOYE, TITILAYO, who is responsible for 1 pending office action. This distribution suggests a balanced prosecution environment where each examiner manages an equal share of the 2 pending actions. Practitioners should prepare for varied examination styles across the 2 distinct art units involved in these proceedings. Navigating multiple art units requires a flexible strategy to address the different technical standards and precedents that may apply to each specific case within the broader biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 1 | 62.2% | +48.0% |
| WANG, CHANG YU | 1 | 33.3% | +53.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18110400 | CELL MEDIUM FORMULATION FOR CELL STABILIZATION | MOLOYE, TITILAYO | 92d overdue |
| 16769985 | CELL SYSTEMS USING SPHEROIDS AND METHODS OF MAKING AND USING THE SAME | WANG, CHANG YU | 56d overdue |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18110400 | CELL MEDIUM FORMULATION FOR CELL STABILIZATION | MOLOYE, TITILAYO | 1632 | §102§103DP | Final Rejection | 92d overdue | Pending | Feb 16, 2023 |
| 16769985 | CELL SYSTEMS USING SPHEROIDS AND METHODS OF MAKING AND USING THE SAME | WANG, CHANG YU | 1675 | DP | Non-Final OA | 56d overdue | Pending | Jun 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAxoSim, Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Titilayo Moloye has the most, with 1 of AxoSim, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.